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sible, as they are more compatible with the concepts of
biosynthesis.
Fucosylation of the two different precursors at the
same position by the Lewis fucosyltransferase results in
the formation of the two immunologically different but
structurally related Lea and Leb antigens (see Fig. 2).3 The
Lewis transferase can also fucosylate two other precur-
sors, formed by the action of the ABH glycosyltrans-
ferases on the H type 1 antigen. These precursors are
known as A and B type 1, respectively, and after fucosy-
lation by the Lewis transferase, they become the ALeb
and BLeb antigens, respectively. The formation of an Lea
structure appears to preclude the action of the secretor
fucosyltransferases. However, it has been recently report-
ed that there is a fucosyltransferase that can affect this
This review covers the basics of Lewis antigens and
their associated phenotypes, and discusses present
problems in serology and future prospects. It briefly
examines the molecular basis for the antigens, and pre-
sents the potential biologic significance of Lewis anti-
gens in fields other than transfusion medicine. For more
comprehensive reviews on the Lewis histo- (tissue-cell)
blood group system and associated secretory pheno-
types, the reader is referred elsewhere.1,2
The Lewis Family: a Disjointed Family With
an Identity Crisis
The Lewis system is best described as a “family” or
“collection” of structurally related antigens. In its
strictest sense, the Lewis system refers only to Lea and
Leb antigens, which are formed by the action of the
Lewis fucosyltransferase on type 1 precursor and H type
1, respectively. Lea and Leb are the two major antigens
that are serologically detected on red cells, and in the
field of transfusion medicine are usually the only recog-
nized antigens of the Lewis system. However, various
other structures, which may or may not have involved
the action of the Le gene that codes for an α1,3/4-fuco-
syltransferase, can also be included in the Lewis system
(see Fig. 1). These antigens include the type 1 precur-
sor, which is the precursor for the Lewis antigens.
Although it does not require the Lewis transferase to be
formed, this antigen may be known as Lec. Strictly
speaking, this is incorrect terminology; however, it is
the original definition and is a convenient term for label-
ing figures. Likewise, the second precursor of Lewis
antigens, H type 1, can also be known by a historical
term, Led. Once again, the Lewis transferase is not
involved in the formation of this antigen; rather, the
secretor transferase is involved. Many have used these
terms to describe antibodies or structures within figures
where space is at a premium. Technically, the terms type
1 precursor and H type 1 should be used whenever pos-
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Fig. 1. The extended Lewis family and relatives. Terminal saccha-
rides defining epitopes of the type 1 Lewis, secretor, and
precursor antigens. Also shown are the type 2 Lewis-relat-
ed antigens, which can be made by the Lewis and secre-
tor fucosyltransferases, but are usually made by other
transferases. The differences between the type 1 and type
2 structures have been highlighted with arrows on the
precursors and the Lea and Lex structures. Not shown are
the blood group B-related structures, which are the same
as the A structures, with the exception that the terminal
α1-3 linked sugar is Gal.
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reaction,4,5 but it is not present (at least not signifi-
cantly) in normal tissues. The ABH, Lewis, and secretor
loci are genetically independent, although the glyco-
syltransferases of these polymorphic blood group sys-
tems interact to produce a range of blood group
structures (as described in Fig. 2 and discussed in detail
in reference 1).
The secretor partnership
Intricately linked with the expression of Lewis anti-
gens is the ABH secretor system. The fucosyltransferase
encoded by this system is genetically independent of
Lewis, although the Lewis and secretor genes are both
on chromosome 19.6 The effect of a secretor transferase
is to terminally α (1,2) fucosylate type 1 precursor and
form H type 1 antigen, which can be utilized by the A,
B, and Le glycosyltransferase, if present.
The Se transferase appears to be in competition with
the Le transferase, and is relatively more efficient
because, when both are present, most of the precursor
is modified into H type 1 (or its related derivatives). The
secretor system is known as such because it controls the
formation of soluble H substances (which can be modi-
fied into A and/or B substances) found in bodily secre-
tions such as saliva and seminal fluid. The blood group
H transferase that forms the H type 2 antigens of red
cells is not expressed in the secretory compartment and
is also ineffective at making H type 1. Therefore, the for-
mation of significant quantities of Leb can be used to
infer the presence of a secretor transferase in persons
expressing a Lewis-positive phenotype.
Most earlier reports (and textbooks) detail a relation-
ship in which the secretor gene regulates the expression
of the H transferase in the secretory tissues.7 This is now
known to be incorrect and is discussed in detail else-
where.2,8 Both the H and Se genes have been cloned
and found to code for distinct but related α(1,2)-fuco-
syltransferases.9 As a consequence, individuals of the
Bombay phenotype can be secretors (and probably
would phenotype as “parabombay”).
An extended family or distant cousins?
The Lewis fucosyltransferase not only has specificity
for the type 1 precursor but can also use the type 2 pre-
cursor to form antigens such as Lex (X), Ley(Y),
ALex(AX), and ALey(AY) (see Fig. 1). These antigens are,
however, most commonly formed by the action of non-
Lewis fucosyltransferases. It is debatable whether these
structures should be considered Lewis-related.
However, because the Lewis transferase can make them,
and these antigens are similar in structure to the type 1
Lewis antigens (they vary only in sugar linkages), it is
not unreasonable to call them Lewis-related. These type
2 Lewis-related structures are often biologically signifi-
cant, but this factor will not be discussed in further
detail in this article.
The secretor fucosyltransferase is equally able to uti-
lize the type 2 precursor10 and form H type 2 and relat-
ed structures. This is in contrast to the H gene-encoded
fucosyltransferase, which preferentially uses the type 2
precursor.10 Because the secretor transferase is not
expressed in the tissues that form the red cells, they are
not responsible for the major type 2 ABH antigens of red
cells. In general, H type 2 and related antigens found in
the epithelial compartments are formed by the secretor
transferase.
Where are Lewis antigens made and where can they
be found?
Lewis antigens are made by glycosyltransferases resid-
Fig. 2. Lewis biosynthetic pathway. Simplified schematic dia-
gram of a hypothesized cyclic pathway of transferase
competition for the formation of type 1 Lewis and
extended Lewis structure in an A1, Le(a–b+) individual
(adapted from reference 3). The apparent differences in
competition between the Se, Le, and A1 transferases have
been schematically shown by the thickness of the path-
way arrows. In the absence of transferase, or in the pres-
ence of alternative transferases, such as A2 and/or B or
Sew, or in different tissues of the same individual, the
type, size, and amount of any glycoconjugate formed will
change depending on the interaction of the transferases
present. The internal reducing side of these glycoconju-
gates is coupled to the carrier (R), which can be glyco-
conjugates of different sizes.
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The Lewis Phenotypes
The Le(a–b+) phenotypic enigma
In healthy white individuals, the interaction of the
fucosyltransferases follows a largely predictable pattern
in the expression of a red cell phenotype (for example,
Fig. 2). That is, when the genotype allows, the type 1
precursor is converted into Lea, or when the Se trans-
ferase is also present, most of the precursor is convert-
ed into H type 1, and lesser amounts are converted into
Lea. The formed H type 1 is then available for conver-
sion into Leb; however, if the A and B transferases are
also present, then much of the H type 1 will be con-
verted to type 1 ABH substances.  
The type 1 A and B antigens that are formed are also
precursors for the Lewis transferase, which can then
convert them into the ALeb or BLeb antigens. However,
Leb is not a suitable precursor for the A or B glycosyl-
transferases. The differing degrees of competition
between the various transferases in individuals (which
are also different in tissues of the same individual) cause
several serologically related phenomena to occur. For
example, in an individual of the A, Se, Le genotype (Fig.
2), the red cells will phenotype as Le(a–b+), and the
amount of Leb on the red cell will be less than that
found on a group O cell. The reason for the Le(a–) result
in phenotyping is because the amount of Lea antigen
formed is much less than Leb, and it is insufficient to
support agglutination with all but the most potent of
reagents. Red cell serologists do not want an Lea-posi-
tive reaction, and serologic reagents have been selected
to comply with this result, i.e., not to react with the
small amounts of Lea present on Le(a–b+) red cells. So,
in theory, there is no such thing as Le(a–b+), but rather
there is a serologically “required” phenotype known as
Le(a–b+). Unfortunately, the secretory system and some
tissues are not so obliging to this “selective blindness,”
because Lea glycoconjugates are clearly present in sali-
va14 and some tissues of Le(a–b+) individuals.2
The formation of less Leb in a group A or a group B
individual is a direct result of competition with the A
and B glycosyltransferase for the available H type 1. This
competition can cause serologic problems because
some anti-Leb reagents (known as anti-LebH) do not
react well with A- or B-modified Leb structures when
they are present in the cell membrane (see reference 1
for further details). If, however, a Lewis reagent is select-
ed that has no preference for the ABO blood type of the
donor (known as anti-LebL), weaker results are still
ing in the Golgi apparatus of cells derived from epitheli-
um.2,11 The amount and type of any particular antigen
made is dependent not only on the activity of the fuco-
syltransferase present but also on other factors, such as,
the precursor type, availability of substrate, and the
compartmental organization of the Golgi apparatus.
Golgi organization is very important because it deter-
mines the order in which a particular transferase has
the opportunity to modify a precursor and what type
of precursor is available for modification. Any change
in the organization of the glycosyltransferases in the
Golgi will have an impact on the type and amount of
any glycoconjugate formed. To date, the Golgi organi-
zation of the Lewis, secretor, ABH, and other competi-
tor glycosyltransferases is not known.
Lewis antigens (and some of their relatives) can
occur as free sugars, or are made on either a backbone
of protein (glycoprotein), or lipid (glycolipid). Lewis
glycoproteins can be found in secretions such as saliva,
milk, or plasma. Lewis glycolipids, in contrast, are
found either circulating as complexes with lipoproteins
in the plasma, or inserted into cell membranes with the
carbohydrate moiety facing the extracellular environ-
ment. The Lewis antigens of red cells, platelets, and
macrophages are not made by the cell per se but are
secondarily acquired from the plasma.12 This acquisi-
tion of glycolipids is a dynamic process as demonstrat-
ed by the phenomenon that a cell having a particular
Lewis phenotype can acquire a new phenotype when
suspended in plasma of a different phenotype (either
in vivo or in vitro). For example, Le(a–b–) red cells
transfused to an Le(a–b+) individual will become
Le(a–b+) after several days, or vice versa, Le(a–b+) red
cells transfused to a Le(a–b–) individual will become
Le(a–b–).13,14 Disease processes, and other conditions,
such as pregnancy and transplantations, can also alter
the expression of Lewis antigens on red cells, although
the amount of Lewis antigen made by an individual
need not necessarily change (as reviewed in reference
1).
Although it is well established that red cells obtain
their Lewis antigens from plasma, the origin of plasma
antigens is still obscure. It has been suggested that they
possibly could originate from the intestinal tract15
because this area has a high concentration of Lewis
antigens. However, this is far from certain. A more
probable explanation is that a variety of exocrine
organs, such as the liver, kidney, pancreas, and the
intestinal tract, all contribute to the plasma glycolipids.
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obtained in non–group O individuals. This weaker reac-
tivity is probably due to less Leb being available for reac-
tivity and differences in avidity of the reagent for the
available structures. As a consequence, non–group O
individuals can easily be mistyped as Leb-negative with
some reagents, a phenomenon that should be avoided.
This problem has unfortunately become more frequent
with the introduction of monoclonal antibodies (per-
sonal observation), which together with the problems
encountered in phenotyping patients can result in mis-
interpretations of clinical data.
The major salivary substances found in an Le(a–b+)
individual are varied and depend on the ABO blood type
of the individual. In a group O, Le(a–b+) individual, H,
Lea, and Leb will be found; however, in a group A indi-
vidual, some or much of the H type 1 (depending on A
subtype) will be converted into A type 1 and ALeb. The
same occurs for B and AB individuals.
The Lewis negative phenotypes are not “all-or-
nothing” phenotypes
In Lewis-negative individuals, no Lewis transferase is
inherited and essentially the biosynthetic pathway of
these individuals is limited to fucosylating or not fucosy-
lating the type 1 precursor. Those who fucosylate the
type 1 precursor make H type 1, which can be modified
into A or B substances, and as a consequence they are
known as secretors (partial secretors also exist, as
described later in this article). Unlike the Lewis-positive
individuals who can be identified as secretors by the
presence of Leb antigen on red cells, the Le(a–b–) secre-
tor phenotype can only be conveniently identified by
testing saliva for the presence of salivary ABH substances.
Those Lewis-negative individuals who do not have a
secretor transferase leave the type 1 precursor unmodi-
fied and do not express salivary ABH substances, even
though they may have active A and/or B glycosyltrans-
ferases.
The Lewis-negative phenotype is not an “all-or-noth-
ing state,” as exemplified by the traces of Lewis activity
that can be immunohistochemically demonstrated in
some tissues.16,17 Serologically, these Lewis antigens are
not reactive on the red cell, but they can be serologi-
cally18 and immunologically detected in saliva, or
immunochemically demonstrated in plasma glycolipid
extracts.3 The Lewis-reactive glycolipids have been
structurally identified, and it also has been shown that
the amount of Lewis antigen made by a Lewis-negative
individual is less than 5 percent of that made by a Lewis-
positive individual.19,20 The products of the Lewis- and
secretor-negative alleles are probably not involved in
forming these aberrant Lewis antigens, but rather other
fucosyltransferases such as FUT5, H, and others may be
involved.
The major salivary substances found in the Le(a–b–)
individual depend on the secretor and ABO genotype of
the individual. The Le(a–b–) nonsecretor expresses in
saliva the type 1 precursor, while the secretor express-
es H type 1 and the corresponding ABH type 1 antigens
in correlation with the red cell phenotype.
The Le(a+b–) phenotype
This is the phenotype of the Lewis-positive nonse-
cretor. This individual does not have a secretor trans-
ferase and so cannot modify the type 1 precursor into H
type 1. As a consequence, no A, B, or H substances are
present in the secretory fluids, and when the Lewis
transferase fucosylates the precursor, monofucosylated
Lea antigen is formed. It should always be realized that
in some populations, many Le(a+b–) individuals may in
fact be Le(a+b+), in which the Leb reaction was not
detected with the reagents being used.21 At the
immunochemical and immunohistological level it can
be demonstrated that true Le(a+b–) individuals, as
opposed to incorrectly phenotyped Le(a+b+) individu-
als, can make trace amounts of Leb antigen,17,22
although the mechanism appears to be different than in
Le(a–b–) individuals.
The major salivary substance found in an Le(a+b–)
individual is essentially just Lea.
The Le(a+b+) and partial-secretor phenotypes
The Le(a+b+) red cell phenotype is rare (or absent)
in Caucasians and should not be confused with the
occasional demonstration of Lea antigens on Le(a–b+)
individuals. The Le(a+b+) phenotype is a common phe-
notype in Polynesians,23 Asians,24 Indonesians,25 and
Australian Aborigines.26,27 The phenotype is probably
much more frequent than is thought but is currently
unrecognized in some populations because of inade-
quate serology. It was originally postulated that the
Le(a+b+) phenotype was caused by an inefficient secre-
tor fucosyltransferase,27 and this was later supported by
eliminating the alternative possibility of a strong Lewis
transferase, which would have the same effect.28
Detailed serologic work has established that the abil-
ity to define the Le(a+b+) phenotype is related to the
reagents used.29 Some reagents are much better than
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chain. An inefficient secretor transferase would allow for
an increase in extended glycoconjugates (see Fig. 2 and
reference 1).
The salivary substances found in Le(a+b+) individu-
als are essentially the same as those found in Le(a–b+)
individuals, except in lesser amounts and in different
proportions. Lea and Leb are usually both well
expressed, and H type 1 may be undetectable in group
A, B, or AB individuals.26
Phenotype frequencies
Phenotype frequencies vary markedly throughout the
world. It is generally accepted that the phenotype fre-
quencies for Europeans are 6 percent Le(a–b–), 22 per-
cent Le(a+b–), and 72 percent Le(a–b+).14 Frequencies
for other populations, especially those where the
Le(a+b+) phenotype can be found, are varied,30 per-
haps reagent dependent, and therefore unreliable. A
good example of this unreliability was demonstrated in
the Taiwanese population in which the frequency of
Le(a+b–) decreased from 10 to 0 percent, while the fre-
quency of Le(a+b+) increased from 13 to 25 percent in
the same population when different reagents were
used.32 A similar phenomenon has been demonstrated
in Polynesians.29
Secretor phenotypes in Europeans are generally
accepted as 80 percent secretors; however, the inci-
dence of secretors is much higher (nearer to 100%) in
dark-skinned people.30 The incidence of the partial-
secretor phenotype has not been defined, and it will
probably be found that many non-European apparent
nonsecretors are, in fact, partial secretors.
The developing Lewis erythrocyte phenotype of
infants
Infants usually phenotype as Lewis negative at birth;
however, this depends on the type and potency of the
reagents used.33 It is generally accepted that there is a
maturation of Lewis and secretor enzymes,2,34 which
causes a progressive change in the phenotype of an
infant from Le(a–b–), to Le(a+b–), then to Le(a+b+),
before finally becoming Le(a–b+) in infants of the Lewis-
positive, secretor-positive genotype.35 As a conse-
quence, an infant’s Lewis phenotype is not reliable until
at least 2 years of age. However, it should be noted that
the infant Le(a+b+) phenotype is unlike the adult
Le(a+b+) phenotype, the latter having a salivary partial-
secretor phenotype and the former a normal-secretor
phenotype.36
others, and only some monoclonal anti-Leb reagents are
able to define the Le(a+b+) red cell phenotype. The
Le(a+b+) phenotype, which has been termed the par-
tial-secretor phenotype,28 is associated with a low
expression of ABH substances in exocrine secretions.
Poor expression of salivary ABH substances is expect-
ed to be associated with the Le(a+b+) phenotype
because the amount of H antigen made in these indi-
viduals is much less, due to stronger competition from
the Le transferase to make Lea from the type 1 precur-
sor, which, when so modified, cannot be further mod-
ified by the Se transferase. In non–group O individuals,
when further demand for available H type 1 is made by
the A and B glycosyltransferases, even less Leb is
formed. This is well demonstrated with the observa-
tion that the Le(a+b+) phenotype is detected more fre-
quently in group O than non–group O individuals.23,30
This phenomenon, in which the antigen level has fall-
en below the level of serologic detection, is identical
to that of the inability to detect Lea present on
Le(a–b+) red cells.
It should be noted that in these Le(a+b+) individu-
als who phenotype as Le(a+b–), Leb reactive sub-
stances are usually present in their saliva. With the
introduction of potent monoclonal reagents, it was not
long before a reagent was found that was sufficiently
potent to react with the Leb of most Le(a+b–) red cells
that had low levels of ABH substances in saliva.31
Although serology had established that the Le(a+b+)
phenotype existed and was associated with a partial-
secretor phenotype, the biochemical basis for the
observed serologic results had not been clarified. This
was achieved by isolating the glycolipids from partial
secretors of the Le(a+b–), Le(a+b+), and Le(a–b–) phe-
notypes, and subjecting them to detailed immunochem-
ical and structural analysis.17,21,28 It was found that
Le(a+b+) individuals, unlike European Le(a–b+) or
Le(a+b–) individuals, coexpressed large amounts of both
Lea and Leb in plasma, the red cell membrane, and small
intestine. A concurrent observation was that in Le(a+b+)
and Le(a–b–) partial secretors, there was a tendency to
produce more elongated glycolipids than in individuals
with a fully functional secretor transferase (i.e.,
Le[a–b+]).17,21 The blood group that results in the most
elongated structures is the Le(a–b–)-nonsecretor pheno-
type.20 The observation that extended glycoconjugates
associated with the partial-secretor phenotype is consis-
tent with the concept that secretor and Lewis fucosyla-
tion prevents extension/elongation of the precursor
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Lewis antigens are differentially expressed in the tis-
sues of the same individual and during development
Although the expression of Lewis antigens in tissues
will not be discussed in this article, it should be appre-
ciated that Lewis and related antigens are differentially
expressed during development37,38 and in different
organs and tissues (see reference 2). For example, in
Le(a–b+) individuals, type-1 ABH antigens and Leb are
expressed in the proximal half of the colon and may
occasionally be present to a limited extent in distal
colonic mucosa. Lea is expressed throughout the colon
of Lewis-positive individuals, irrespective of the ABH
secretor status. In the fetal colon and rectum, type 1
Lewis and ABH-related carbohydrate blood group sub-
stances are expressed and directly related to the secre-
tor status of the individual. However, during the
neonatal period these antigens gradually disappear or
are reduced appreciably in the colon, with the excep-
tion of Lea, which remains expressed.
Lewis Phenotyping Reagents
In general, Lewis phenotyping reagents are of poor
quality, both in the past when only polyclonal reagents
were available and now with the monoclonal reagents
that are used. The problem with monoclonal reagents is
not necessarily in their specificity or avidity but rather
with their current serologic requirements. The Lewis sys-
tem is generally considered (from a transfusion perspec-
tive) to be a clinically insignificant blood group system.
The failure to detect Lewis antibodies that are reactive
below 30°C is desirable, because these antibodies will
not cause a transfusion problem.39 Furthermore, inac-
curate phenotyping of Lewis antigens does not pose a
transfusion risk, because if the antigen is poorly
expressed on a red cell it is unlikely to cause a transfu-
sion reaction. This lack of a requirement for an accurate
phenotype has been reflected in the quality of serologic
reagents available. As a consequence, blood bank
reagents may not necessarily give an accurate Lewis phe-
notype, although the phenotype they provide is satis-
factory for transfusion needs.
Lewis antibodies are crossreactive because Lewis anti-
gens have closely related epitopes, which in all cases are
sufficiently close to a related structure that they will
crossreact.1,40 For example, all monoclonal anti-LebL
reagents (which this investigator is aware of) that are
used in red cell serology are, in fact, anti-Leab reagents
that react as well with the Leb antigen as they do with the
Lea antigen but do not show this Lea specificity with red
cells. However, if one tries to use these serologic anti-
LebL reagents on anything other than red cells (e.g., to
test for Leb antigens in saliva or on tissues), Lea antigens
will react with these anti-LebL reagents.
The blood group substances in saliva
The blood group substances in saliva are traditionally
tested for by obtaining boiled saliva and using it to inhib-
it various antibodies (after suitable dilution of both the
antiserum and saliva). Testing for salivary substances is
fraught with hazards (for further details, see reference 1).
For the detection of the large amounts of salivary ABH
substances found in secretor individuals, simple method-
ology is usually adequate14; however, low levels of ABH-
reactive antigens, which are present in the saliva of
Le(a+b–) and Le(a+b+) individuals, must be consid-
ered.41,42 Lewis antigens that are present in large
amounts in the saliva of Lewis-positive individuals are
also present in trace amounts in Lewis-negative individ-
uals.18,43 As a consequence, the assays used must be suf-
ficiently insensitive as to not detect the trace amounts of
salivary ABH substances in nonsecretors or Lewis sub-
stances in Lewis-negative individuals. The assay should,
however, be sufficiently sensitive to be able to delineate
salivary nonsecretors from salivary partial secretors. This
is complex and requires careful methodologic approach-
es and even then, in some instances, cannot be achieved.
In blood group serology, monoclonal antibodies have
generally replaced polyclonal reagents, and the reactivi-
ty of these reagents with salivary substances can be
markedly different from reactivity of polyclonal reagents.
For example, it has been demonstrated that some mon-
oclonal anti-A reagents are much more sensitive to neu-
tralization by nonsecretor saliva,44 and all monoclonal
anti-LebL reagents used for red cell phenotyping will be
neutralized by salivary Lea and related substances (see
above).
The H type 2 antigen is also present in saliva (and relat-
ed ABH, Lex, and Ley structures); however, the formation
of this antigen in saliva is not controlled by the H fuco-
syltransferase but rather by the Se fucosyltransferase.45
H type 2 is the antigen in saliva that is detected by the
lectin Ulex europeaus.46
There has been a tendency for some serologists not to
use anti-A and anti-B reagents, and instead rely only on H
lectin (anti-H) to determine a salivary phenotype. In
order to get an accurate phenotype, one must use
reagents that correlate with the ABO type of the individ-
ual, e.g., if an individual is group A, then inhibition tests
I M M U N O H E M A T O L O G Y ,  V O L U M E  1 2 ,  N U M B E R  2 ,  1 9 9 6 57
Lewis antigens and associated phenotypes
must be done against anti-A and anti-H (or H lectin). The
reason for this is that in a group A individual, particular-
ly group A1, much of the detectable H substance may
have been converted into A substance, which will not
inhibit the H reagent.
One of the more difficult problems in salivary ABH
phenotyping is obtaining suitable controls. In reality, this
is an easy problem to solve, as boiled saliva samples will
store frozen for many years, but in practice very few lab-
oratories have acquired such samples. Controls for sali-
vary phenotyping must be used and should be suitable
to control the reagent being inhibited, e.g., for salivary
anti-A inhibition, the controls must be from both a group
A secretor and a group A nonsecretor. The same applies
for the other ABO groups. When working with popula-
tions that have the partial-secretor phenotype, a larger
range of controls and titration of the saliva is required,
although even then some very weak partial secretors
may not be separable from nonsecretors.
Is it possible to get an accurate Lewis phenotype?
Obtaining a phenotype is never a problem because a
phenotype is merely the expression seen; however,
obtaining a Lewis phenotype that bears some correlation
with the genotype and is reproducible is much more dif-
ficult. An accurate Lewis phenotype is possible, in spite
of the problems mentioned above, but only by using
carefully controlled techniques. For example, in red cell
phenotyping, group A1 Le(a–b+) red cells should be used
as the Leb-positive control. Only then can you be assured
of detecting the common Lewis phenotypes. If the
Le(a+b+) phenotype exists in your population, then you
need to know if your reagent can detect the weak
expression of Leb on these cells, and use appropriate
reagents and controls.
In salivary ABH phenotyping, controls must be appro-
priate for the ABH phenotype of the test sample and anti-
sera (see above). Saline must not be used as the
nonsecretor control. Furthermore, unless a monoclonal
reagent has been specifically tested against a range of
well-characterized saliva samples, polyclonal anti-A, anti-
B (preferably from a nonimmunized donor), and Ulex
europaeus lectin should be used. Saliva phenotyping
must never be done using H lectin only. It should also be
noted that the partial-secretor phenotype can only be
defined by titration studies.
One form of validating a phenotype is to use two or
more reagents of the same specificity. Unfortunately, this
approach may not be helpful as many commercial sup-
pliers buy the same clone, which they dilute and pack-
age differently, and do not usually advise the purchaser
of the clone used. We have evaluated monoclonal
reagents from different suppliers that reacted by differ-
ent techniques, gave different serologic results, and were
later found to be from the same clone.
Although an inaccurate Lewis phenotype is not a
major problem for a blood bank, it is of major impor-
tance to researchers who are trying to establish the rela-
tionships of the histo-blood group antigens with
genotype or disease. It should always be remembered
that it is much more difficult to obtain an accurate Lewis
phenotype from a diseased, transfused, or pregnant per-
son than it is from a healthy blood donor.
Molecular Genetics
The coding sequences of both the wild Lewis47 and
secretor9 genes have been determined. It has been found
that Lewis-negative and nonsecretor alleles are each col-
lections of alleles with point mutations that inactivate
the cognate enzyme9,25,48-52 (see Table 1). There are
Table 1. Known genetic mutations modifying the peptide sequence and enzyme expression of secretor (FUT2) and Lewis (FUT3) fucosyltransferases
Secretor (FUT2) Mutations
Nucleotide Amino acid
Position Wild Variant Position Wild Variant Effect Reference
385 A T 129 Iso Phe Less enzyme 67
428 G A 143 Trp stop Inactivating 9
571 C T 191 Arg stop Inactivating 52,67
Lewis (FUT3) Mutations
Nucleotide Amino acid
Position Wild Variant Position Wild Variant Effect Reference
59 T G 20 Leu Arg Partial inactivating 25
202 T C 68 Trp Arg Inactivating 48
314 C T 105 Thr Met Inactivating 49
508 G A 170 Gly Ser Inactivating 50,51
1067 T A 365 Ile Lys Inactivating 25
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also partially active (Lew, Sew) transferases coded by alle-
les in both systems. The T59 partial-inactivating muta-
tion of Lewis causes a negative expression of Lewis on
red cells but allows Lewis antigens to be expressed in
saliva.25 This allele is usually present with a second fully
inactivating mutation.48,53 A point mutation at
nucleotide 385, which is expressed in a homozygous
state, or in a heterozygous state with a nonsecretor
allele, has now been identified in all Le(a+b+) or weak-
secretor individuals tested of both Polynesian and
Indonesian descent (unpublished observation).
Informative family studies show correlation of this
genetic point mutation with the Le(a+b+) and with the
partial-secretor phenotype. This candidate Sew allele has
been successfully cloned, and expression studies prove
that this point mutation results in poor expression of the
secretor transferase (Sew status).67
Kinetic and acceptor substrate specificity patterns
suggest the 385 mutated enzyme and the wild-type
enzyme have the same substrate affinity (Km). However,
about five times less enzyme activity (Vmax) is present
in cells expressing the 385 mutated enzyme than in
those expressing the wild-type enzyme. This suggests
the basis of Sew is a mutation at nucleotide 385, result-
ing in a product that is more susceptible to proteolysis
and its catabolism is accelerated.67
Although molecular typing may appear as an attractive
alternative to phenotyping (in view of the difficulties in
obtaining an accurate phenotype), this option cannot be
used until all alleles have been defined. In spite of this,
when an accurate phenotype is required, molecular biol-
ogy should be used to confirm the serologic phenotype,
and any discrepancies should be investigated at the phe-
notypic, molecular, and genotypic levels.
Biological Significance of Lewis Antigens
The transfusion significance of Lewis antibodies has
been reviewed elsewhere39,54 and will not be reiterat-
ed in this article.
The monomorphic type 2 Lewis antigens are clearly
associated with biological functions (as reviewed in ref-
erence 2). Although it is known that the Lewis trans-
ferase can make these antigens, the contribution, if any,
of the Lewis system to the biological functions/pro-
cesses associated with the type 2 antigens is not known.
Instead, the potential biological significance of type 1
Lewis antigens will be briefly examined. It should first
be noted that a lack of both Le and Se fucosyltransferas-
es does not lead to a recognized pathologic condition.
It is possible, however, that Le and Se fucosyltransferas-
es are desired polymorphisms that divert glycoconju-
gates from extension, sialylation, or branching
pathways,3 because at least one or the other of the Le or
Se transferase is present in all dark-skinned populations
and in almost all other populations.
Studies of disease associations with Lewis is a com-
plex area, beset with controversy, inaccurate data, and
in most instances, a reliance on statistical analysis. Many
of the problems that arise in these studies are caused by
inadequacies in accurately phenotyping diseased indi-
viduals. While some studies have been well performed,
most have not fully investigated all the parameters
involved. Any disease association with Lewis must con-
sider all the phenotypic parameters of ABH, Lewis, and
secretor, and now should also include genotype.
Furthermore, tissue expression (both in health and dis-
ease) of the antigens should be considered, because the
red cell phenotype does not always reflect the Lewis
and related antigens expressed in different tissues of the
same individual.2
However, Lewis is clearly associated with, or in genet-
ic linkage with, factors causing certain diseases, in par-
ticular, peptic ulcers, ischemic heart disease, lung
function, kidney transplant rejection, and cancer (as
reviewed in references 14 and 55–61).
Genetically polymorphic structures like Lewis con-
tribute to the diversity of cell surface markers and thus
to the cell, tissue, individual, and species specificity.
They may also play a role in interactions with microor-
ganisms expressing specific lectins at their surfaces. For
example, the pathogen Helicobacter pylori has a lectin
(adhesin) for the Leb structure.62 Other microorganisms
also have developed recognition systems for histo-blood
groups and related antigens because glycolipids on host
cells have been found to interact with proteins of viral
and bacterial parasites (reviewed in reference 63). It is
of interest to note that in some populations living in
tropical conditions, the incidence of Lewis antibodies is
much higher than expected, suggesting environmental
factors.25
Lewis antigens may also play a role in transplant sur-
vival. It was originally suggested that Lewis antigens
have a role in kidney transplant rejection.57
Unfortunately, the reliability of the serology in some
studies is debatable, and so the actual role of Lewis in
renal transplant rejection still remains unresolved. It is
clear, however, that Lewis antibodies are cytotoxic64
and can affect kidney function.65,66
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There are many other apparent but inconclusive asso-
ciations of disease with Lewis phenotypes that will not
be reviewed in this article. The involvement of the
Lewis system in disease is clearly complex and appears
to be only one of several factors involved in some dis-
ease processes.
The potential biological significance of Lewis is an
area that has not yet been thoroughly or accurately
explored. Careful, systematic, and scientific studies are
now required to determine the extent of involvement of
the Lewis and related type 1 antigens in disease.
Final Comment
The Lewis system is perhaps the most complicated
blood group system in humans. The type, amount, and
size of a particular antigen formed depend on the inter-
action of a range of products coded by alleles of at least
three genetically independent loci: Lewis, secretor, and
ABH. Red cell phenotyping, the most common method
of determining a Lewis phenotype, is dependent on the
secondary acquisition of the antigens from the plasma,
and the problems associated with that acquisition,
together with inadequacies in phenotyping. The Lewis
system is also historically plagued with nomenclature
controversies, published inaccuracies, and a lack of sta-
tus as a “transfusion significant” system, which has made
the Lewis system an area of low importance to many
blood group serologists.
However, in light of the biologic potential of the
Lewis system in transplantation and disease processes,
it is now time to be progressive and treat the Lewis sys-
tem (at least for work other than transfusion) as an
important one. Methodology, reagents, controls, and
education are all areas requiring attention so that infor-
mative phenotypes can be obtained. Molecular geno-
typing can also now be used to support the serologic
phenotype, and the biologic significance of the Lewis
histo-blood group system should now be properly exam-
ined. There are still many enigmas in the Lewis system
waiting to be resolved.
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